How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%
The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today.
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago.
LivaNova: Economics Should Start Making Sustained Improvements
LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth.
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.
LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today.
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
